Geron Corporation . California-based BioTime Inc. announced on January 7 that it will buy Geron Corporation's human embryonic stem cell assets, which includes intellectual property, 400 patents and patent applications, and the first ever US Food and Drug Administration-approved Phase I clinical trial of a hESC therapy.
http://www.sbwire.com/press-releases/trend-analysis-report-on-nasdaq-stocks-nasdaq-gern-nasdaq-ocz-195268.htm
http://www.sbwire.com/press-releases/trend-analysis-report-on-nasdaq-stocks-nasdaq-gern-nasdaq-ocz-195268.htm
No comments:
Post a Comment